{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T01:08:49Z","timestamp":1767229729074,"version":"3.48.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T00:00:00Z","timestamp":1752883200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T00:00:00Z","timestamp":1752883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urogynecol J"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00192-025-06216-9","type":"journal-article","created":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T11:32:15Z","timestamp":1752924735000},"page":"2427-2434","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of the Safety of Virtual Visits After In-Clinic Botox\u00ae Injection: A Quality Improvement Study"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1987-8409","authenticated-orcid":false,"given":"K. Marie","family":"Douglass","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Laus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"DeAndrade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taylor","family":"Whitaker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tajnoos","family":"Yazdany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Truong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,19]]},"reference":[{"issue":"1","key":"6216_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/nau.20798","volume":"29","author":"BT Haylen","year":"2010","unstructured":"Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, et al. An International Urogynecological Association (IUGA)\/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010;29(1):4\u201320.","journal-title":"Neurourol Urodyn"},{"issue":"6","key":"6216_CR2","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","volume":"20","author":"WF Stewart","year":"2003","unstructured":"Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327\u201336.","journal-title":"World J Urol"},{"issue":"1","key":"6216_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/JU.0000000000003985","volume":"212","author":"AP Cameron","year":"2024","unstructured":"Cameron AP, Chung DE, Dielubanza EJ, Kaufman MR, Alanee S, Gupta P, et al. The AUA\/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder. J Urol. 2024;212(1):11\u201320.","journal-title":"J Urol"},{"key":"6216_CR4","first-page":"493","volume-title":"Urogynecology and reconstructive pelvic surgery","author":"SM Hartigan","year":"2021","unstructured":"Hartigan SM, Dmochowski RR. Overactive bladder syndrome, polyuria, and nocturia. In: Barber M, Bradley C, Walters M, Karram M, editors. Urogynecology and reconstructive pelvic surgery. 5th ed. Amsterdam: Elsevier; 2021. p. 493\u2013522.","edition":"5"},{"key":"6216_CR5","first-page":"523","volume-title":"Urogynecology and reconstructive pelvic surgery","author":"M Bradley","year":"2021","unstructured":"Bradley M, Amundsen C. Refractory overactive bladder. In: Barber M, Bradley C, Walters M, Karram M, editors. Urogynecology and reconstructive pelvic surgery. 5th ed. Amsterdam: Elsevier; 2021. p. 523\u201338.","edition":"5"},{"issue":"10","key":"6216_CR6","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1111\/ijcp.12443","volume":"68","author":"KD Sievert","year":"2014","unstructured":"Sievert KD, Chapple C, Herschorn S, Carl S, R\u00fcbben H, Jones G, et al. OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder. Int J Clin Pract. 2014;68(10):1246\u201356.","journal-title":"Int J Clin Pract"},{"issue":"6","key":"6216_CR7","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1016\/j.juro.2012.12.022","volume":"189","author":"VW Nitti","year":"2013","unstructured":"Nitti VW, Dmochowski R, Herschorn S, Sand PK, Thompson C, Nardo C, et al. EMBARK Study Group. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo-controlled trial. J Urol. 2013;189(6):2186\u201393.","journal-title":"J Urol"},{"issue":"2","key":"6216_CR8","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1002\/nau.24871","volume":"41","author":"WS Reynolds","year":"2022","unstructured":"Reynolds WS, Suskind AM, Anger JT, Cameron AP, Stothers L, O\u2019Donnell M, et al. Incomplete bladder emptying and urinary tract infections after botulinum toxin injection for overactive bladder: multi-institutional collaboration from the SUFU research network. Neurourol Urodyn. 2022;41(2):662\u201371.","journal-title":"Neurourol Urodyn"},{"issue":"3","key":"6216_CR9","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00192-021-04691-4","volume":"33","author":"SE Eckhardt","year":"2022","unstructured":"Eckhardt SE, Takashima Y, Handler SJ, Staskin DR, Griebling TL, Gormley EA, et al. Antibiotic regimen and route of administration do not alter rates of urinary tract infection after intravesical botulinum toxin injection for overactive bladder. Int Urogynecol J. 2022;33(3):703\u20139.","journal-title":"Int Urogynecol J"},{"key":"6216_CR10","unstructured":"BOTOX\u00ae (onabotulinumtoxinA) for injection, for intramuscular, intradetrusor, or intradermal use [Allergan \u00ae Highlights of Prescribing Information]. Accessed 12 July 2024. Available from: https:\/\/media.allergan.com\/actavis\/actavis\/media\/allergan-pdf-documents\/product-prescribing\/20190620-BOTOX-100-and-200-Units-v3-0USPI1145-v2-0MG1145.pdf."},{"issue":"6","key":"6216_CR11","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1097\/SPV.0000000000000496","volume":"24","author":"D Liberman","year":"2018","unstructured":"Liberman D, Milhouse O, Johnson-Mitchell M, Reynolds WS, Dmochowski RR. Real-world retention rates after intravesical onabotulinumtoxinA for idiopathic overactive bladder. Female Pelvic Med Reconstr Surg. 2018;24(6):404\u20137.","journal-title":"Female Pelvic Med Reconstr Surg"},{"issue":"4","key":"6216_CR12","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/SPV.0000000000001001","volume":"27","author":"ER Aldrich","year":"2021","unstructured":"Aldrich ER, Pauls RN. Routine office assessment after onabotulinumtoxinA injection for overactive bladder is unnecessary to detect clinically significant voiding dysfunction. Female Pelvic Med Reconstr Surg. 2021;27(4):225\u20139.","journal-title":"Female Pelvic Med Reconstr Surg"},{"issue":"12","key":"6216_CR13","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1136\/bmjqs-2015-004411","volume":"25","author":"G Ogrinc","year":"2016","unstructured":"Ogrinc G, Davies L, Goodman D, Batalden P, Davidoff F, Stevens D. SQUIRE 2.0 (Standards for QUality Improvement Reporting Excellence): revised publication guidelines from a detailed consensus process. BMJ Qual Saf. 2016;25(12):986\u201392.","journal-title":"BMJ Qual Saf"},{"issue":"1","key":"6216_CR14","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/AOG.0000000000003320","volume":"134","author":"A Davenport","year":"2019","unstructured":"Davenport A, Stark S, Quian A, Kaufman MR, Kowalik C, Cameron AP, et al. A patient-centered approach to refractory overactive bladder and barriers to third-line therapy. Obstet Gynecol. 2019;134(1):141\u20138.","journal-title":"Obstet Gynecol"},{"issue":"5","key":"6216_CR15","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1097\/JU.0000000000001950","volume":"206","author":"S Iyer","year":"2021","unstructured":"Iyer S, Amegashie C, deMartelly V, Reynolds WS, Kaufman MR, Cameron AP, et al. Patient perceptions impact progression to third-line therapy for treatment of overactive bladder. J Urol. 2021;206(5):1240\u20137.","journal-title":"J Urol"},{"key":"6216_CR16","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1097\/JU.0000000000000509","volume":"203","author":"DJ Lightner","year":"2020","unstructured":"Lightner DJ, Wymer K, Sanchez J, Kavoussi L. Best practice statement on urologic procedures and antimicrobial prophylaxis. J Urol. 2020;203:351.","journal-title":"J Urol"},{"issue":"3","key":"6216_CR17","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.eururo.2011.10.028","volume":"61","author":"P Denys","year":"2012","unstructured":"Denys P, Le Normand L, Ghout I, Karsenty G, Amarenco G, De Seze M, et al. VESITOX Study Group in France. Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study. Eur Urol. 2012;61(3):520\u20139.","journal-title":"Eur Urol"},{"issue":"1","key":"6216_CR18","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1159\/000316080","volume":"86","author":"RM Bauer","year":"2011","unstructured":"Bauer RM, Gratzke C, Roosen A, Buchner A, Soljanik I, Bastian PJ, et al. Patient-reported side effects of intradetrusor botulinum toxin type A for idiopathic overactive bladder syndrome. Urol Int. 2011;86(1):68\u201372.","journal-title":"Urol Int"},{"issue":"2","key":"6216_CR19","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.eururo.2013.04.001","volume":"64","author":"C Chapple","year":"2013","unstructured":"Chapple C, Sievert KD, MacDiarmid S, Khullar V, Radziszewski P, Nardo C, et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2013;64(2):249\u201356.","journal-title":"Eur Urol"}],"container-title":["International Urogynecology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-025-06216-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00192-025-06216-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-025-06216-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T01:04:11Z","timestamp":1767229451000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00192-025-06216-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,19]]},"references-count":19,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["6216"],"URL":"https:\/\/doi.org\/10.1007\/s00192-025-06216-9","relation":{},"ISSN":["0937-3462","1433-3023"],"issn-type":[{"type":"print","value":"0937-3462"},{"type":"electronic","value":"1433-3023"}],"subject":[],"published":{"date-parts":[[2025,7,19]]},"assertion":[{"value":"24 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A version of this work was previously presented at the American Urogynecologic Society (AUGS) Annual Meeting in Washington, DC, USA on 25 October 2024.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Prior Presentation"}},{"value":"The study was approved by the Harbor-UCLA Institutional Review Board (IRB #32617\u201301).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"IRB Approval"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}